PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies side effects and best dose of PSCA-chimeric antigen receptor (CAR)
T cells in treating patients with prostate stem cell antigen positive (PSCA+) castration
resistant prostate cancer that has spread to other places in the body (metastatic). PSCA-CAR
T cells are immune cells that have been engineered in the laboratory to kill tumor cells.
This is done by using a virus to insert a piece of deoxyribonucleic acid (DNA) into the
immune cells that allows them to recognize prostate tumor cells. It is not yet known how well
PSCA-CAR T cells works in killing tumor cells in patients with metastatic castration
resistant prostate cancer.